All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 4

JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
ROBERT BUTORA

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
KURT SCHRADER Former member of Congress

Previously held: Former Member of Congress

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4818
Treat and Reduce Obesity Act of 2023
S 2407
Treat and Reduce Obesity Act of 2023

Lobbying activity 7

Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies.

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Defense

Issues related to pharmaceutical manufacturing and development.

Pharmacy

Drug importation, prescription drug safety, value and access.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.